Highlights Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 06:00:00 2024-06-19 pm EDT			5-day change	1st Jan Change
19.82 ^CAD	+0.66%		+1.59%	-6.29%

Jun. 20	Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	MT
Jun. 20	J&J: launches open, secure digital ecosystem	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	Jun. 20	MT
J&J: launches open, secure digital ecosystem	Jun. 20	CF
J&J: promising results in Crohn's disease	Jun. 20	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	Jun. 20	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	Jun. 20	DJ
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	Jun. 17	CI
J&J: positive results in Sjögren's disease	Jun. 17	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	Jun. 17	MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	Jun. 15	CI
EU regulator mandates label updates on CAR-T cancer therapies	Jun. 14	RE
J&J: encouraging trial in relapsing multiple myeloma	Jun. 14	CF
J&J: the promise of ibrutinib in CLL	Jun. 14	CF
J&J: promising results for Imbruvica in leukemia	Jun. 14	CF
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	Jun. 14	MT
Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma	Jun. 14	CI
High-risk health workers can get routine Ebola vaccine, Gavi says	Jun. 13	RE
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager	Jun. 13	MT
High-risk health workers can get routine Ebola vaccine, says Gavi	Jun. 13	RE
Cancer victims ask court to block J&J talc bankruptcy	Jun. 12	RE
Sector Update: Health Care Stocks Softer Late Afternoon	Jun. 11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST